ExodusPoint Capital Management LP Invests $677,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

ExodusPoint Capital Management LP acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 88,187 shares of the company's stock, valued at approximately $677,000. ExodusPoint Capital Management LP owned about 0.24% of iTeos Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in ITOS. Trexquant Investment LP raised its stake in shares of iTeos Therapeutics by 267.2% during the fourth quarter. Trexquant Investment LP now owns 179,966 shares of the company's stock worth $1,382,000 after buying an additional 130,960 shares during the last quarter. Geode Capital Management LLC boosted its stake in iTeos Therapeutics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 644,901 shares of the company's stock valued at $4,954,000 after acquiring an additional 4,551 shares during the last quarter. Wellington Management Group LLP grew its holdings in iTeos Therapeutics by 4.3% during the 4th quarter. Wellington Management Group LLP now owns 110,332 shares of the company's stock worth $847,000 after acquiring an additional 4,563 shares during the period. JPMorgan Chase & Co. raised its position in shares of iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock valued at $15,888,000 after acquiring an additional 1,601,477 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of iTeos Therapeutics in the 4th quarter valued at $229,000. 97.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ITOS. Wells Fargo & Company decreased their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th. HC Wainwright restated a "buy" rating and set a $46.00 target price on shares of iTeos Therapeutics in a research report on Thursday, March 6th. JPMorgan Chase & Co. cut their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th.

iTeos Therapeutics Stock Down 3.2 %

Shares of ITOS traded down $0.20 on Thursday, hitting $6.02. The company's stock had a trading volume of 73,535 shares, compared to its average volume of 467,776. The firm's fifty day moving average price is $6.63 and its 200-day moving average price is $7.76. iTeos Therapeutics, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.75. The firm has a market capitalization of $229.85 million, a price-to-earnings ratio of -1.91 and a beta of 1.43.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. As a group, equities analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.